Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

230 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
IRBs During COVID-19: Tried and True.
McMillan G. McMillan G. Narrat Inq Bioeth. 2021;11(1):89-94. doi: 10.1353/nib.2021.0038. Narrat Inq Bioeth. 2021. PMID: 34334482
The Common Denominator.
McMillan G. McMillan G. Narrat Inq Bioeth. 2017;7(1):47-50. doi: 10.1353/nib.2017.0015. Narrat Inq Bioeth. 2017. PMID: 28713143
Perceptual Consequences of Cochlear Deafferentation in Humans.
Bramhall NF, McMillan GP. Bramhall NF, et al. Among authors: mcmillan gp. Trends Hear. 2024 Jan-Dec;28:23312165241239541. doi: 10.1177/23312165241239541. Trends Hear. 2024. PMID: 38738337 Free PMC article. Review.
Oddball paradigm complexity in multi-token auditory evoked potentials.
Billings CJ, Madsen BM, Grush LD, Koerner TK, McMillan GP, Bologna WJ. Billings CJ, et al. Among authors: mcmillan gp. Neurosci Lett. 2022 Sep 25;788:136856. doi: 10.1016/j.neulet.2022.136856. Epub 2022 Aug 24. Neurosci Lett. 2022. PMID: 36029915
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
Munro APS, Feng S, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, Bula M, Cathie K, Chatterjee K, Dodd K, Enever Y, Qureshi E, Goodman AL, Green CA, Harndahl L, Haughney J, Hicks A, van der Klaauw AA, Kanji N, Libri V, Llewelyn MJ, McGregor AC, Maallah M, Minassian AM, Moore P, Mughal M, Mujadidi YF, Holliday K, Osanlou O, Osanlou R, Owens DR, Pacurar M, Palfreeman A, Pan D, Rampling T, Regan K, Saich S, Bawa T, Saralaya D, Sharma S, Sheridan R, Thomson EC, Todd S, Twelves C, Read RC, Charlton S, Hallis B, Ramsay M, Andrews N, Lambe T, Nguyen-Van-Tam JS, Snape MD, Liu X, Faust SN; COV-BOOST study group. Munro APS, et al. Lancet Infect Dis. 2022 Aug;22(8):1131-1141. doi: 10.1016/S1473-3099(22)00271-7. Epub 2022 May 9. Lancet Infect Dis. 2022. PMID: 35550261 Free PMC article. Clinical Trial.
230 results